Merck & Co. (MRK) Stake Decreased by Cwm LLC
Cwm LLC decreased its stake in Merck & Co. (NYSE:MRK) by 28.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,328 shares of the company’s stock after selling 88,483 shares during the period. Cwm LLC’s holdings in Merck & Co. were worth $12,578,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Burke & Herbert Bank & Trust Co. increased its stake in Merck & Co. by 4.3% in the first quarter. Burke & Herbert Bank & Trust Co. now owns 25,862 shares of the company’s stock valued at $1,368,000 after buying an additional 1,059 shares in the last quarter. Alpha Windward LLC increased its stake in Merck & Co. by 0.9% in the first quarter. Alpha Windward LLC now owns 4,941 shares of the company’s stock valued at $261,000 after buying an additional 42 shares in the last quarter. Capital Investment Advisors LLC increased its stake in Merck & Co. by 12.4% in the first quarter. Capital Investment Advisors LLC now owns 48,868 shares of the company’s stock valued at $2,586,000 after buying an additional 5,386 shares in the last quarter. Mission Wealth Management LLC increased its stake in Merck & Co. by 176.0% in the first quarter. Mission Wealth Management LLC now owns 46,333 shares of the company’s stock valued at $2,451,000 after buying an additional 29,543 shares in the last quarter. Finally, Iberiabank Corp increased its stake in Merck & Co. by 6.7% in the first quarter. Iberiabank Corp now owns 84,035 shares of the company’s stock valued at $4,446,000 after buying an additional 5,308 shares in the last quarter. Hedge funds and other institutional investors own 72.93% of the company’s stock.
Merck & Co. (NYSE:MRK) traded up 0.81% during midday trading on Friday, reaching $62.41. 13,605,282 shares of the company traded hands. The company’s 50-day moving average price is $62.76 and its 200 day moving average price is $58.03. The firm has a market capitalization of $172.58 billion, a PE ratio of 34.23 and a beta of 0.63. Merck & Co. has a 12 month low of $47.97 and a 12 month high of $64.00.
Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The firm had revenue of $9.84 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period last year, the firm posted $0.86 EPS. Merck & Co.’s quarterly revenue was up .6% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co. will post $3.75 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be given a $0.46 dividend. The ex-dividend date of this dividend is Tuesday, September 13th. This represents a $1.84 dividend on an annualized basis and a yield of 2.95%. Merck & Co.’s dividend payout ratio (DPR) is 101.10%.
MRK has been the topic of several research analyst reports. Goldman Sachs Group Inc. reissued a “neutral” rating and set a $60.00 target price on shares of Merck & Co. in a research report on Wednesday, June 8th. Argus reaffirmed a “buy” rating on shares of Merck & Co. in a report on Thursday, June 9th. Jefferies Group dropped their price objective on shares of Merck & Co. from $54.00 to $53.00 and set a “hold” rating on the stock in a report on Tuesday, June 14th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $62.00 price objective on shares of Merck & Co. in a report on Tuesday, June 28th. Finally, Vetr raised shares of Merck & Co. from a “sell” rating to a “buy” rating and set a $62.26 price objective on the stock in a report on Monday, July 4th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of €63.20 ($70.23).
In related news, EVP Clark Golestani sold 3,000 shares of Merck & Co. stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of €63.03 ($70.03), for a total value of €189,090.00 ($210,100.00). The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Weir Mirian M. Graddick sold 45,000 shares of Merck & Co. stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of €57.99 ($64.43), for a total transaction of €2,609,550.00 ($2,899,500.00). Following the completion of the transaction, the insider now owns 123,151 shares in the company, valued at €7,141,526.49 ($7,935,029.43). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by corporate insiders.
Merck & Co. Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Stock Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related stocks with our FREE daily email newsletter.